Newron Pharmaceuticals S.p.A. | Finanzwire

Basculer en Français

10057	Companies
205564	Keywords
135810	Articles
108991	Press releases

Headlines Articles Press releases Newron Pharmaceuticals S.p.A.

Home
Companies
Newron Pharmaceuticals S.p.A.

BRIEF

published on 03/24/2025 at 17:50, 11 months 27 days ago

Newron Pharmaceuticals Nominates Dr. Chris Martin as Independent Chairman

Board Of Directors Newron Pharmaceuticals Chris Martin Biopharma Leadership Schizophrenia Therapy
PRESS RELEASE

published on 03/24/2025 at 17:45, 11 months 27 days ago

Newron proposes renowned biopharma company founder and entrepreneur Dr. Chris Martin for election as Independent Chairman
Newron Pharmaceuticals S.p.A. proposes Chris Martin, ex-CEO of ADC Therapeutics, as Independent Chairman succeeding Dr. Köstlin after 12 years. Martin an experienced biopharma leader

Chairman Biopharma Newron Pharmaceuticals Chris Martin ADC Therapeutics
BRIEF

published on 01/09/2025 at 07:05, 1 year 2 months ago

Newron and Myung In Pharm License Agreement for Evenamide in South Korea

Phase III Trial CNS Therapies Evenamide Schizophrenia Treatment License Agreement
PRESS RELEASE

published on 01/09/2025 at 07:00, 1 year 2 months ago

Newron and Myung In Pharm announce license agreement for evenamide in South Korea
Newron Pharmaceuticals S.p.A. and Myung In Pharm enter license agreement for evenamide in South Korea, aiming to develop innovative treatment option for schizophrenia patients

Newron Pharmaceuticals Evenamide License Agreement South Korea Myung In Pharm
BRIEF

published on 12/13/2024 at 07:05, 1 year 3 months ago

Newron and EA Pharma Sign License Agreement for Evenamide in Asia

Newron Pharmaceuticals Evenamide Schizophrenia Treatment License Agreement EA Pharma
PRESS RELEASE

published on 12/13/2024 at 07:00, 1 year 3 months ago

Newron and EA Pharma (a subsidiary of Eisai Co., Ltd.) announce license agreement for evenamide in Japan and other Asian territories
Newron Pharmaceuticals S.p.A. and EA Pharma (a subsidiary of Eisai Co., Ltd.) have signed a license agreement for evenamide in Japan and other Asian territories, aiming to address unmet medical needs in patients with schizophrenia

Schizophrenia Newron Pharmaceuticals Evenamide License Agreement EA Pharma
BRIEF

published on 09/19/2024 at 07:05, 1 year 6 months ago

Newron Pharmaceuticals Presents H1 2024 Results and Business Update

Clinical Trials Newron Pharmaceuticals Evenamide Schizophrenia Treatment H1 2024
PRESS RELEASE

published on 09/19/2024 at 07:00, 1 year 6 months ago

Newron presents H1 2024 results and provides business update
Newron Pharmaceuticals presents H1 2024 financial results and operational highlights, focusing on evenamide studies for schizophrenia treatment and corporate developments

Financial Results Newron Pharmaceuticals Evenamide Schizophrenia Treatment H1 2024
BRIEF

published on 06/25/2024 at 17:50, 1 year 8 months ago

Newron Pharmaceuticals Highlights 2024 Investor Day in NYC

Investor Day Clinical Trials Schizophrenia Newron Pharmaceuticals Evenamide
PRESS RELEASE

published on 06/25/2024 at 17:45, 1 year 8 months ago

Newron Pharmaceuticals reports on its 2024 Investor Day in New York City
Newron Pharmaceuticals reports on its 2024 Investor Day in New York City, highlighting evenamide's potential in treating treatment-resistant schizophrenia. Leading experts present clinical data and benefits of evenamide

Clinical Data Schizophrenia 2024 Investor Day Newron Pharmaceuticals Evenamide

Accesswire

Published on 03/20/2026 at 13:30, 6 hours 34 minutes ago

Unusual Machines Announces Pricing of Approximately $150 Million Public Offering of Common Stock
Published on 03/20/2026 at 12:30, 7 hours 34 minutes ago

CANEX Metals Announces the Numbers of Gold Basin Shares Taken up by Canex Metals
Published on 03/20/2026 at 12:00, 8 hours 4 minutes ago

Organto Foods Inc. Announces Marketing Engagements with VSA Capital Limited and Venture Liquidity Partner Ltd.
Published on 03/20/2026 at 03:10, 16 hours 54 minutes ago

Future Fuels Announces Filing of Amended and Restated Life Offering Document
Published on 03/20/2026 at 00:20, 19 hours 44 minutes ago

Prospect Ridge To Host Investor Webinar With Presentation And Audience Q&A

View all ACCESSWIRE

EQS Group

Published on 03/20/2026 at 19:06, 57 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 03/20/2026 at 18:29, 1 hour 35 minutes ago

EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Full year figures in line with guidance – reduced earnings in Q4 2025/26
Published on 03/20/2026 at 17:50, 2 hours 13 minutes ago

Funding Circle Holdings plc: Transaction in Own Shares
Published on 03/20/2026 at 17:47, 2 hours 17 minutes ago

EQS-Adhoc: ZhongDe Waste Technology AG: Suspension of the revocation of the admission of ZhongDe Waste Technology AG shares to trading on the regulated market (General Standard)
Published on 03/20/2026 at 17:03, 3 hours ago

Edison issues report on Deutsche Beteiligungs (DBAN)

Les Echos

Published on 03/20/2026 at 19:00, 1 hour 4 minutes ago

AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 18:15, 1 hour 49 minutes ago

Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 17:45, 2 hours 19 minutes ago

Cie du Bois Sauvage : Annual report 2025
Published on 03/20/2026 at 16:57, 3 hours 7 minutes ago

Number of shares and voting rights - February 2026 (In French only)
Published on 03/19/2026 at 18:00, 1 day 2 hours ago

Filing of the 2025 Universal Registration Document

View all LES ECHOS COMFI WIRE